Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

<p>Supplemental Table S2 - Differential expression analysis of genes in leukemic or immune cells treated with sEV</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Ernesto Gargiulo (15134961) (author)
Eará dahkkit:	Elodie Viry (15134964) (author), Pablo Elías Morande (15134967) (author), Anne Largeot (15134970) (author), Susanne Gonder (15134973) (author), Feng Xian (15134976) (author), Nikolaos Ioannou (15134979) (author), Mohaned Benzarti (15134982) (author), Felix Bruno Kleine Borgmann (15134985) (author), Michel Mittelbronn (15134988) (author), Gunnar Dittmar (15134991) (author), Petr V. Nazarov (15134994) (author), Johannes Meiser (15134997) (author), Basile Stamatopoulos (15135000) (author), Alan G. Ramsay (15021857) (author), Etienne Moussay (15135003) (author), Jérôme Paggetti (15135006) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Tumor Biology Immuno-oncology Methods and Technology Hematological Cancers Leukemias Lymphomas Immunology T cell exhaustion Tumor resistance to immune response Preclinical Models Animal models of cancer Tumor Microenvironment Immune cells and the microenvironment
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Supplementary Table S3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Dahkki: Ernesto Gargiulo (15134961)
Almmustuhtton: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
Dahkki: Andrew Nguyen (17142197)
Almmustuhtton: (2025)

Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Dahkki: Shih-Shih Chen (15314296)
Almmustuhtton: (2025)

Supplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Dahkki: Shih-Shih Chen (15314296)
Almmustuhtton: (2025)

Supplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Dahkki: Shih-Shih Chen (15314296)
Almmustuhtton: (2025)

Supplementary Figure S4 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Dahkki: Shih-Shih Chen (15314296)
Almmustuhtton: (2025)

Supplementary Figure S5 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Dahkki: Shih-Shih Chen (15314296)
Almmustuhtton: (2025)

Supplementary Figure S6 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Dahkki: Shih-Shih Chen (15314296)
Almmustuhtton: (2025)

Supplementary Table S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Dahkki: Shih-Shih Chen (15314296)
Almmustuhtton: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Dahkki: Yu Chen (1234761)
Almmustuhtton: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Dahkki: Yu Chen (1234761)
Almmustuhtton: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Dahkki: Yu Chen (1234761)
Almmustuhtton: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Dahkki: Yu Chen (1234761)
Almmustuhtton: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Dahkki: Andrew O. Yam (15293045)
Almmustuhtton: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Dahkki: Andrew O. Yam (15293045)
Almmustuhtton: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Dahkki: Andrew O. Yam (15293045)
Almmustuhtton: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Dahkki: Andrew O. Yam (15293045)
Almmustuhtton: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Dahkki: Andrew O. Yam (15293045)
Almmustuhtton: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Dahkki: Erika Y. Faraoni (14844897)
Almmustuhtton: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Dahkki: Erika Y. Faraoni (14844897)
Almmustuhtton: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Dahkki: Erika Y. Faraoni (14844897)
Almmustuhtton: (2025)

Table S1 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Dahkki: Fanfan Fan (16799646)
Almmustuhtton: (2025)

Table S2 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Dahkki: Fanfan Fan (16799646)
Almmustuhtton: (2025)

Table S3 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Dahkki: Fanfan Fan (16799646)
Almmustuhtton: (2025)

Table S4 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Dahkki: Fanfan Fan (16799646)
Almmustuhtton: (2025)

Table S5 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Dahkki: Fanfan Fan (16799646)
Almmustuhtton: (2025)

Table S6 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Dahkki: Fanfan Fan (16799646)
Almmustuhtton: (2025)

Table S7 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Dahkki: Fanfan Fan (16799646)
Almmustuhtton: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
Dahkki: Isha Mondal (16721699)
Almmustuhtton: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Dahkki: Dahihm Kim (16546203)
Almmustuhtton: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Dahkki: Dahihm Kim (16546203)
Almmustuhtton: (2025)

Cannot write session to /tmp/vufind_sessions/sess_900u0k9evsd2caqnvtev7dnls7